| Ytd | -34.34% | |
| 1y | 21.62% |
| Open | 6.85 | Prev Close | 6.90 | Low | 6.60 | High | 6.85 | Mkt Cap | 262.82M |
| Vol | 354.43K | Avg Vol | 369.25K | EPS | -3.96 | P/E | N/A | Forward P/E | -5.54 |
| Beta | -0.27 | Short Ratio | 11.43 | Inst. Own | 80.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 6.97 | 200-d Avg | 9.56 | 1yr Est | 26.43 |
TRDA News
-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support p
BlackRock Inc. purchased a new stake in Entrada Therapeutics, Inc. (NASDAQ: TRDA) during the undefin
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $1.01 per share versus the Zacks
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.01) per share which beat the ana
-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELE
Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference
Guggenheim analyst Debjit Chattopadhyay maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy a
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that an independent Data Monitoring Committ
-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 --
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced
NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
ATLANTA, May 18, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Entrada Ther
LOS ANGELES, May 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights lit
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Entrada Therapeutics, Inc. (TRDA) Q1 2026 Earnings Call Transcript
Wall Street analysts changed outlook on top names. Check all changes on analyst ratings page. See wh
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Entrada Therapeutics (NASDAQ:TRDA)
Dow falls over 100 points, S&P 500 and NASDAQ also down. Tech sector up, energy stocks down. US
Entrada Therapeutics stock plunged after the Duchenne trial data missed investor expectations despit
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.95) per share which beat the ana
Oppenheimer analyst Francois Brisebois maintains Entrada Therapeutics (NASDAQ:TRDA) with a Outper
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.94) per share which beat the ana
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA)
-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201 ---- Co
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Entrada Therapeutics (NASDAQ:TRDA)
-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-20
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.06) per share which missed the a
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.04) per share which missed the a
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA)
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.42) per share which beat the ana
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA)
Gainers Sera Prognostics, Inc. (NASDAQ: SERA) shares surged 63.4% to $2.11 after the company anno
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 296% to $3.71 after the company announce
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares rose 158% to $2.42 in pre-market trading after
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.